RhoGAM, or immune globulin (immuneglobulin), is used to prevent hemolytic diseases of the newborn (HDN), in Rh-negative mothers that have had to give birth to Rh+ infants. This case involves a client who had an unplanned vaginal delivery. The labor and delivery nurse confirmed that the client is Rh negative and that her baby is Rh positive. The paper will cover RhoGAM including the route of administration and nursing implications as well as indications and contraindications.
Route of Administration
Intramuscular injection is the best way to administer RhoGAM. The recommended dose of RhoGAM for Rh-negative mothers is 300 micrograms (μg) at 28 weeks of gestation and within 72 hours of delivery if the infant is Rh-positive. RhoGAM should only be administered within 72-hours of a miscarriage.
The administration of RhoGAM is primarily performed by nurses. Before administering RhoGAM, the nurse should verify the client’s blood type and the infant’s blood type. RhoGAM will not be necessary if the infant has Rh-negative. Also, the nurse needs to ensure informed consent from the client for RhoGAM administration.
The nurse should administer RhoGAM within 72 hours of delivery to prevent the development of Rh antibodies in the mother’s blood. A nurse must also be on the lookout for signs of an allergic reaction, including fever, chills and anaphylaxis. The nurse must immediately stop administering the infusion and inform the doctor if there is an allergic reaction.
RhoGAM can be used in Rh-negative mothers, who gave birth to Rh+ infants. Rh-negative mothers who have a Rh+ fetus run the risk of becoming pregnant to an Rh-negative baby. HDN may be caused by future pregnancies due to maternal sensitization. HDN may cause severe fetal anemia and jaundice as well as brain damage and death. RhoGAM prevents maternal sensitization against the Rh antigen.
RhoGAM should not be administered to Rh-positive mothers or mothers already sensitive to Rh. RhoGAM should be avoided in mothers who have had an adverse reaction to human globulin or have received an incompatible transfusion. RhoGAM should be avoided by mothers with bleeding disorders or thrombocytopenia.
RhoGAM, an important medication that prevents HDN in Rh negative mothers who gave birth to Rh positive infants, is concluded. RhoGAM should be administered intramuscularly within 72 hours after delivery. The administration of RhoGAM is a crucial task for nurses. They should verify that clients have given their informed consent and check the baby’s blood type. RhoGAM contraindicated for Rh-positive mothers, mothers already sensitive to Rh antigens and others. To ensure optimal outcomes for mother and baby, it is crucial for healthcare professionals to be familiarized with RhoGAM’s proper administration.